Please assess the completion status of the following clinical trial:

Trial Title: Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaker~* Currently taking 17-beta-estradiol tablet daily via sublingual or oral route on dose therapeutic for gender-affirming therapy; steady dose for at least 4 weeks~* Serum estradiol and testosterone levels within target therapeutic range (75-200 pg/mL and \<55 ng/dL, respectively)~Exclusion Criteria:~* Active or history of deep venous thrombosis/pulmonary embolism~* Active or recent (within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction)~* Liver dysfunction~* History of breast cancer~* History of orchiectomy~* Known sensitivity or allergy to any components of the study medication~* Taking potent CYP3A4 inhibitors or inducers

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PO then SL (Type: ACTIVE_COMPARATOR): Subjects will administer 17-beta-estradiol orally (PO) for Study Day 1-14, followed by administration of 17-beta-estradiol sublingually (SL) for Study Day 15-28.
- SL then PO (Type: ACTIVE_COMPARATOR): Subjects will administer 17-beta-estradiol sublingually (SL) for Study Day 1-14, followed by administration of 17-beta-estradiol orally (PO) for Study Day 15-28.

Based on this trial design, predict the completion outcome and termination type (if applicable).